PubMed Health⌕ Search

Biomedical subjects

S K Grebe

Publications and source records attributed to S K Grebe.

22 records · Page 2Linked to original sources
PubMed1992

Treatment of extensively invasive (giant) prolactinomas with bromocriptine.

We report four cases of extensively invasive giant prolactinomas. No tumour was suitable for total or near total resection because of invasion into surrounding bone. All had undergone radiotherapy prior to dopamine agonist therapy. Prolactin levels were between 103,000 mlU/L and 1,700,000 mlU/L at presentation, but all tumours responded to bromocriptine therapy and prolactin levels fell into the normal range in three patients within two to 24 months. The fourth patient's level fell to just above the reference range (700 mlU/L) within 36 months. None of the patients has died of their pituitary tumour or related complications to date. Giant prolactinomas appear to be exquisitely sensitive to treatment with bromocriptine. The role of radiotherapy is unclear, but it might contribute to long term control. Surgery should be limited to control of local complications.

Adult↗
PubMedDate not supplied

Sarcomatoid carcinoma of the prostate: progression from adenocarcinoma is associated with p53 over-expression.

BACKGROUND: The pathogenesis of sarcomatoid metaplasia of prostatic adenocarcinoma is uncertain. The histologic features of sarcomatoid carcinoma arising in two patients with previously irradiated prostatic adenocarcinoma are reported and the relationship between prostatic adenocarcinoma and subsequent sarcomatoid carcinoma is investigated by immunohistochemical detection of epithelial and soft tissue tumor markers, and p53 protein. METHODS AND RESULTS: Two patients, aged 72 and 67 years, underwent localized radiotherapy for prostatic adenocarcinoma and re-presented with sarcomatoid carcinoma 41 months and 60 months later, respectively. In both cases the tumor consisted of anaplastic spindle cells with occasional osteoclast-like giant cells. The initial tumors showed immunohistochemical staining typical of prostatic adenocarcinoma with absence of expression of p53 protein. The subsequent sarcomatoid carcinomas were positive for vimentin and negative for epithelial cell markers. In both cases serial biopsies showed a temporal increase in tumor expression of p53 protein. CONCLUSIONS: The development of sarcomatoid carcinoma in prostatic adenocarcinoma is associated with progressive accumulation of p53. This is suggestive of increasing clonal dominance of dedifferentiated tumor cells carrying p53 mutations.

Adenocarcinoma↗
PubMedDate not supplied

Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model.

BACKGROUND: Shark cartilage and shark cartilage extracts have been reported to have anti-angiogenic and anti-neoplastic properties. This study reports the effects of oral administration of powdered shark cartilage on tumor progression in a murine renal tumor model. MATERIALS AND METHODS: Renal tumors were induced in CBA female mice by a single bolus of IV streptozotocin. 57 mice were fed shark cartilage and the numbers and rate of development of dysplastic convoluted tubules, papillary and solid renal epithelial tumors was compared with 57 control mice over an 88 week follow-up period. RESULTS: In the shark cartilage fed group dysplasia was first observed after 23 weeks (control 19 weeks), papillary tumors after 24 weeks (control 23 weeks) and solid tumors after 55 weeks (control 19 weeks). There was no significant difference in the rate of development of dysplastic tubules between test and control animals. The development of papillary and solid tumors was significantly delayed in the test group. CONCLUSIONS: In this tumor model oral shark cartilage delays, but does not abolish, tumor progression.

Administration, Oral↗